EGFR NSCLC Osimertinib — RACP Adult Medicine MCQ

Instant feedback + full explanation. One question, done properly.

EasyMedical OncologyEGFR NSCLC OsimertinibRACP Adult Medicine

A 58-year-old woman with metastatic NSCLC (EGFR exon 19 deletion). First-line therapy?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: D — Osimertinib

EGFR-mutant NSCLC: osimertinib first-line (FLAURA trial – superior OS over 1st-gen TKIs). Monitor for ILD and QTc.

Reference: Cancer Council – 2021; PBS – 2025